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Glioblastoma (WHO Grade IV) is both the most common primary brain tumor and the most malignant. Advances in the
understanding of the biology of the tumor are needed in order to obtain a clearer picture of the mechanisms driving these
tumors. To neuropathologists, glioblastoma is a tumor that represents a complex system of migrating pleomorphic tumor cells,
proliferatingbloodvessels,inﬁltratinginﬂammatorycells,andnecrosis.Thisreviewwillhighlighthowthegliomastemcellconcept
bringstheseelementstogetherintoacollectivewhole,interactingwithmicroenvironmentalinﬂuencesincomplexways.Borrowing
from chaos theory a vocabulary of “self organizing systems” and “complex adaptive systems” that seem useful in describing these
pathologic features, a new paradigm of glioblastoma biology will be proposed that genetic changes should be understood in a
three dimensional framework as they relate not only to the tumor cells themselves but also to the multicellular hierarchical unit,
not isolated from, but responsive to, its local milieu. In this way we will come to better appreciate the impact our therapeutic
interventions have on the regional phenotypic heterogeneity that exists within the tumor and the intercellular communications
directing adaptation and progression.
Glioblastoma (WHO Grade IV) is both the most common
primary brain tumor and the most malignant. Advances in
the understanding of the biology of the tumor are needed
in order to obtain a clearer picture of the mechanisms
driving these tumors. The advances obtained to date have
challenged those of us who work with glioblastoma on
a daily basis to keep opposing ideas in our minds. For
example,whileglioblastomaisauniformdiagnosticcategory
of astrocytic tumors, the intertumoral and intratumoral
histologic heterogeneity within them reﬂects a chaotic
diversity of cell types and mesenchymal backgrounds. Also,
while molecular data indicate that these tumors have a
hypermutable genotype [1] and many diﬀerent cytologic
repertoires [2, 3] available to them, recurrences often exhibit
histologic features similar to the primary tumors (personal
observation). What is driving the microenvironmental orga-
nization of necrosis and microvascular proliferation that
these tumors recapitulate so robustly as to represent the
key diagnostic features [4] of the tumor, however, is not
clear. The recent identiﬁcation of malignant cells within
glioblastomas with stem-cell-like qualities provides insights
into these questions. Furthermore the recent advances in
chaos theory have provided a vocabulary of “self organizing
systems” and “complex adaptive systems” that seem useful
in describing these pathologic features. In order to better
understand where we are now, it is useful to review
some early conceptual issues related to grading malignant
astrocytomas.
In the 1920s, Bailey and Cushing proposed a cytoge-
netic paradigm of glioblastoma classiﬁcation in which a
relationship between gliomas and undiﬀerentiated cells in
glioblastomas was hypothesized [5]. This immediately fell
under attack as the embryologic systems had no equivalent
of a glioblast. Indeed, a major problem of the cytogenetic
system was that it classiﬁed glioblastomas as de novo tumors,
ignoring elements of intermediate diﬀerentiation and malig-
nant progression from lower grade tumors. Subsequently,
malignant progression was approached by Kernohan [6],
Ringertz [7], and Earle and colleagues [8]i nav a r i e t y
of ways. The major problem inherent in the cytogenetic2 Journal of Oncology
approach lay not only in its neglect of the nonglial features of
the tumors including angiogenesis, mesenchymal elements,
a n de v e nn e c r o t i cf o c it h a th a v eb e c o m el a n d m a r k so f
grading the tumor [4, 9] but also they all emphasize a
linearity in progression from early tumor to later tumor
that are not found in nature. Rather, the appearance of
glioblastoma histology is one of explosive growth with
a rapid appearance of mesenchymal features not evident
in lower grade tumors. The recent description of glioma
cells with stem cell qualities and mesenchymal interactions
provides a nidus of organization around which accelerated
growth, therapeutic resistance, and mesenchymal prolifera-
tion appear to be centered. As such, the glioma stem cells
provide a potential unifying concept with which to better
understand the histologic appearances of these tumors.
The concept of a malignant cell with stem cell qualities
arose very early in the history of anatomic pathology as
Virchow, himself, noted the similarities between certain can-
cers and embryogenetic processes and ascribed the origins
of cancers to embryonic rests (for which proof resides in
certain pediatric brain tumors [10]). Subsequently, other
researchers found evidence to support the presence of a
rare cell in tumors capable of regenerating the tumors and
forming colonies in cell culture (reviewed in [11]). However,
the origin of these purported tumor stem cells is not at all
clear. In contrast to embryogenesis where the normal stem
cell has a known origin from primitive precursors, the tumor
stem cell origin from stem cells versus transient amplifying
cells derived from stem cells versus dediﬀerentiated mature
cells is far from being solved.
The possibility of brain tumor stem cells arose from the
concepts proposed in 1982 by ML Rosenblum and colleagues
who hypothesized inherent diﬀerences in the sensitivity
of clonogenic cells as an explanation for clinical drug
failure, tumor heterogeneity, and age-response relationships
[12]. This was followed by the demonstration of complex
heterogeneity in the human glioma cell line, D54, and eight-
derived clones by Wikstrand and colleagues establishing
the intrinsic biologic variation that seemed to underlie
the multiagent resistance of glioblastoma [13]. Singh and
colleagues in the Dirks laboratory [14], working on pediatric
brain tumors, were also struck by the heterogeneity of these
tumors with respect to proliferation and diﬀerentiation and
their similarity to human leukemia. In leukemias, tumor
clones exhibit hierarchical organization originating from
rare leukemic stem cells that possess extensive proliferative
and self-renewal potential and are responsible for maintain-
ing the tumor clone [15, 16]. Similar cells with stem-like
qualities were subsequently conﬁrmed in the solid tumor
systems, glioma [17] and adenocarcinoma of the breast [18].
Singh and colleagues used the cell surface marker CD133
(prominin-1) to sort out a clonogenic population of cells
demonstrating stem-like features in medulloblastomas and
pilocytic astrocytomas with capabilities of self-renewal and
multilineage diﬀerentiation and declared these cells to be
brain tumor stem cells [14]. Several groups later conﬁrmed
theseﬁndingsinotherbraintumors,includingglioblastomas
[19, 20]), medulloblastomas [14, 21, 22], and low grade
gliomas [14], and ependymomas [23] also display functional
heterogeneity with a potential hierarchy of diﬀerentiation
like that noted in a stem cell system.
The tumor stem cell hypothesis adds to the conventional
cytogenetic theory in ways that are both complementary
and explanatory. The conventional approach hypothesizes a
probabilistic approach to clonal emergence within a tumor
mass whereby a “lucky” cell happens to exhibit those
properties necessary to survive, recur, or spread within its
microenvironmental setting. It implies that the “lucky” cells
are not necessarily similar in any way; chance places a cell
with the correct combination of abilities in the right place to
surviveandprogress.However,researchintothegliomastem
cells described above has revealed attributes within a minor
population of tumor cells that have signiﬁcantly altered our
thinking. These ﬁndings indicate that while the masses of
tumorcellsareclonalandshareacommoncytogenesis,there
is a hierarchical growth pattern within the tumor with cells
capable of adaptive responses to the microenvironment in a
way that not only maintains the cellular heterogeneity of the
tumor but also uses this heterogeneity to manifest emergent
behaviors of tumor progression. These rare cells exhibit fea-
tures of a central organizer. The role of organizing and driv-
ing tumoral adaptation in glioblastomas occurs in a number
of ways, such as supporting growth, promoting heterogene-
ity, endowing therapeutic resistance, and remodeling the
mesenchymal and microvascular environment (Figure 1).
In 2006, Bao and colleagues [24], using the CD133
antibody, selected cells from glioblastoma biopsies that were
not only capable of forming tumorspheres in culture but also
demonstrated self-renewal and multilineage diﬀerentiation.
An immunohistochemical interrogation of these CD133+
cells further revealed the coexpression of a number of
markers commonly associated with benign stem cells includ-
ing SOX2, Musashi, and Nestin. The tumorspheres, when
transplanted into nude mouse intracranial models, were
capable of forming tumors recapitulating the glioblastoma
phenotype. In contrast, the CD133 negative (CD133−)c e l l s
could neither form spheroids in normoxic conditions nor
form tumors when xenografted. However, when cocultured
with CD133+ cells, the CD133− cells formed tumors, the
xenograft implantation rate of which was dose dependent
upon the percentage of cocultured CD133+ cells. When
biopsies of glioblastomas were investigated, CD133+ cells
proved to be a minor population of cells varying from 1 to
3% of total tumor cell population; however, clinical studies
suggestedthatthepercentageofCD133+cells[25,26]orrate
of tumorsphere formation [27, 28] predicted overall survival
of the patient (although contrary evidence also exists [29]).
In their initial paper, Bao and colleagues found that
CD133+ cells constitutively activated the DNA repair genes
CHK1 and CHK2 at much higher levels than CD133− cells,
and this expression mediated resistance to X-irradiation.
When the checkpoint response enzymes were speciﬁcally
inhibited, the CD133+ cells became as susceptible to radia-
tion as the CD133− cells [24].
The CD133+ cells were also found to exhibit features
indicative of an abrogation of programmed cell death
pathways. Programmed cell death is necessary for the
maintenance of a normal healthy cellular population and isJournal of Oncology 3
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Figure 1: The concept of a self-organizing system with emergent properties as related to glioblastoma.
frequently implicated in cell death due to chemotherapeutic
interventions. For survival, tumors must overcome natural
self-destruction signals generated by these internal and
external signals. In normal development, MYC drives the
undiﬀerentiated states of developing progenitor cells by
combining with Max, a prodiﬀerentiation agent. Gradually,
Mad proteins displace Myc from the MYC-Mad duplex
allowing the formation of Max-Mad complexes which elicit
diﬀerentiation inducing signals. However, recent studies
indicate that MYC proteins are overexpressed in glioma
stem cells and drive not only an undiﬀerentiated state but
also trigger an antiapoptotic, prolife signaling cascade in
the cells [30–32]. A prominent upstream factor stabilizing
MYCcomplexesistheHIF2αpathway,animportantpathway
relatedtohypoxia thatisdiscussedinmoredetailbelow [33].
AnothermajorregulatorofcellsurvivalinGSCsistumor
necrosis factor alpha-induced protein 3 (TNFAIP3), or A20.
Hjelmeland [34] determined that A20 is overexpressed in
glioma stem cells relative to nonstem glioblastoma cells.
Elevated levels of A20 in glioma stem cells contribute to
apoptotic resistance via loss of susceptibility to TNFα-
induced cell death. A20 knockdown sensitized GSCs to
TNFα-mediated apoptosis as well as decreased GSC survival,
self-renewal, and tumor growth. These ﬁndings contrast to
lymphomas in which loss of A20 via mutations suggests that
A20 acts as a tumor suppressor. These data suggest that
A20 may function as a tumor enhancer in glioma through
promotion of glioma stem cell survival.
In like kind to benign neural stem cells [35], the
organizational signiﬁcance of rare glioblastoma cells with
stem-cell-like qualities extends far beyond the conﬁnes of the
cell’s cytoplasmic borders. Rather, the major organizational
and adaptational impact of CD133+ cells lies in their
inﬂuence on the cells and mesenchymal elements about
them. Recent studies have revealed a potential amplifying
feedback mechanism to be extant between CD133+ and
CD133− cells involving the progrowth factor, Interleukin 6
(IL6). Recent studies by Wang and colleagues [36] indicate
that the CD133− cells express IL6 but express few, if any,
receptor components on their cell surface. However, the
CD133+ cells express the components of IL6 receptor, gp160
and IL6 receptor alpha, on their cell surface while making
less IL6 itself. The signiﬁcance of IL6 lies in the fact that its
signals promote STAT3 activation in GBM cells in vitro, and4 Journal of Oncology
targeting of either STAT3 or IL6 decreases GBM cell survival
[37–40] and appears to promote invasion [41]. Additional
reports also link STAT3 to stem cell biology as STAT3 is
required to maintain the propagation and pluripotency of
normal embryonic stem cells, neural stem cells [42–44],
and glioblastoma stem cells [40, 45]. Also STAT3 has been
linked to mesenchymal diﬀerentiation in glioblastoma cells,
aphenotypeofclinicalaggressivenessandpoorsurvival[46].
Furthermore, clinically IL6 is important as the quantitative
load of IL6 and its receptors also correlate inversely with
patient survival [47].
The extra-cellular inﬂuence of CD133+ cells is also
manifest on the stromal cells about them. Histologically,
brain tumor stem cells seem to prefer a perivascular niche
[48–50], a location that recapitulates the normal neural stem
cells and the vasculature of the developing central nervous
system [35, 51]. Glioma stem cells have been shown to
mediate vascular proliferation in glioblastomas via Vascular
Endothelial Growth Factor (VEGF). VEGF is chemically
activated via the Hypoxia Inducible Factor (HIF) pathway.
In glioblastomas, HIF1α is found in all malignant cells, while
HIF2α expression is unique to glioma stem cells. Under mild
hypoxic conditions, HIF2α is stabilized preferentially while
HIF is not present, leaving HIF2α as the active primary
signaling agent driving the downstream expression of VEGF.
However, the hierarchical interplay between glioma stem
cells and vessels is not for nutritional needs alone as the
gliomastemcellshavealsobeenfoundtoexpressthelaminin
receptor, integrin α6.
This integrin is a key receptor for laminins found in
the extracellular matrix (ECM) of vessels. Integrin α6i s
produced in the glioma stem cells and is found to mediate
growth and maintenance of glioma stem cells by knockdown
studies. This is signiﬁcant in that the extracellular matrix
surrounding normal neural stem cells is known to provide
both structural and instructive cues [52] within the CNS.
Several reports have suggested that ECM structures originat-
ing from blood vessels in the adult neural stem cell germinal
zones are critical in preserving their maintenance through
serving as a reservoir for growth factors [53]. Thus, the
potentiality of a perivascular niche rich in oncogenic signals
further highlights the interplay at work among glioma stem
cells, malignant nonstem glioma cells, and the mesenchymal
elements earlier appreciated by Rubinstein and other pathol-
ogists. Indeed, the ﬁndings strengthen the declaration that
tumors are aberrant organ systems that display a complex
organizational interplay among neoplastic cells, recruited
vascular, inﬂammatory, and stromal elements [54].
The perivascular niche is also important to stem cell
physiology. Oxygen tension is tightly regulated in normal
development with low oxygen tension associated with
maintenance of an undiﬀerentiated state. Hypoxia promotes
the self-renewal of embryonic stem cells and prevents the
diﬀerentiation of neural stem cells in vivo [55–57]. Hypoxia
is also likely to be a functional component of a normal stem
cell niche as well. Hematopoietic stem cells are maintained
in bone marrow within hypoxic niches [58]. In regards
to this, hypoxia has been shown to increase expression
of stem cell markers in neuroblastomas, erythroleukemia,
and cell lines [59–61]. These ﬁndings suggested to Li
and colleagues [62] that the hypoxic environment of a
glioblastoma may promote stem cell survival. Indeed, they
found that targeting HIFs in glioma stem cells inhibited self-
renewal, proliferation, and survival in vitro and attenuated
tumor initiation potential of these cells in vivo. They found,
as well, that HIF2α expression correlated with poor patient
survival. Heddleston and colleagues [33] followed with data
indicating that hypoxia promoted the self-renewal capability
of the stem and nonstem population as well as promoted a
more stem-like phenotype in the nonstem population. This
was corroborated by increased tumorsphere formation as
well as upregulation of important stem cell factors, such
as OCT4, NANOG, and MYC. The importance of HIF2α
was also supported via experiments demonstrating that
forced expression of nondegradable HIF2α induced a cancer
stem cell phenotype as well as augmented the tumorigenic
potential of the nonstem population. Furthermore, HIF2α
is known to mediate changes associated with clinically
aggressive behavior including dissemination as well as angio-
genesis.Thissusceptibilityofthenonstemgliomapopulation
to transition to a stem-like phenotype emphasizes the
importance of microenvironmental inﬂuences on the tumor
and the remarkable capacity within glioma cells to adapt to
hypoxia.
The multiple potentialities of a subpopulation of gli-
oblastoma cells for self-maintenance, multilineage diﬀeren-
tiation, and self-renewal identify them as having stem cell
like qualities. However, the complex interactions among
stem cells, nonstem cells, and mesenchymal cells mediate
the cytologic heterogeneity well recognized by neuropathol-
ogists for decades. The presence of cells with embryonal
features further lends support to these features identiﬁed
by the earliest neuropathologists. The presence of vascular
proliferation as a required component for grading tumors
marks astrocytoma as the only tumor system in which the
vascular component is a requisite feature for characterizing
prognosis. Details identiﬁed by glioma stem cell researchers
have characterized a more complex interaction than was
previously appreciated.
Modern research makes clear that glioblastomas do not
behave as an organic whole; geographic heterogeneity arises
as the tumor regionally adapts to the microenvironment
the individual cell clusters ﬁnd themselves in (Figure 2). For
example, recent studies have indicated that antiangiogenic
therapy results in short-term tumor burden control but
does not aﬀect overall survival. Rather, escape mechanisms
include some tumors responding with migration, producing
the gliomatosis cerebri state (19567589) or responding with
increases in basic Fibroblast Growth Factor (bFGF), Stro-
mal cell-derived factor 1α (SDF1α), and viable circulating
endothelial cells (CECs) [63]. In this regard, the tumor
b e h a v e sa sac o m p l e xa d a p t i v es y s t e m[ 64] exhibiting emer-
gent behavior. While the main body of tumor is relatively
homogeneous with respect to genotype (driving genetic
mutations) [65], it is heterogeneous with respect to pheno-
typic diversity; the oﬀspring of glioma cells not only diverge
and diﬀerentiate cytologically, but the stem-cell oﬀspring are
also driven to seek viable options. Furthermore, evidenceJournal of Oncology 5
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Figure 2: Microhomogeneity of a glioblastoma. (a) H&E stained
section demonstrating two distinct cell morphologies with a nodule
of large cells in the lower center surrounded by small cells in
the upper portions of the photograph. (b) MIB-1 immunohis-
tochemistry demonstrates the nodule of large cells in the lower
center to have a low proliferation index relative to the small cells.
(c) Neuroﬁlament protein immunohistochemistry shows axons
coursing through the small cells in the upper left region of the
tumor (asterisk) with loss of axons in the upper right (arrowhead)
and in the nodule of large cells (arrow).
suggests that remnant clones of earlier stages remain as
reserve cells, capable of generating tumoral renewal. Adapta-
tional forces resulting from microenvironmental inﬂuences
of hypoxia, vascularity, acidic stress, starvation, exogenous
growth factors, and altered responses to endogenous growth
factors as well as exogenous factors including therapeutic
interventions seem to be dealt with in an ecological fashion
as the oﬀspring occupy niches.
But is the ecological model the correct model to use?
How de novo tumors arise is not known. Our understanding
of cancer suggests that de novo tumors arise in the same
way as progressive tumors, just that the de novo tumor
arises more rapidly. However, it is not clear how the many
genetic mutations arise in the de novo tumors and how
the tumors arise without passing through slower growing
intermediate stages. In these situations of explosive growth,
the whole manifests itself in a total that is greater than the
sum of its parts. In other words, is ecological succession
necessarily at play in these tumors or do the tumor cells
escape true ecological selection via unknown, nonlinear
mechanisms through which emergent glioblastoma behavior
is manifest? In nonlinear systems, the end is exquisitely
sensitive to initial conditions; subtle changes in starting
conditionsresultinprofoundlyvariableresults.Ifthisreﬂects
reality in glioblastoma, what roles do the glioma stem cells
play as tumor initiating cells?
In this regard, as anticipated by Ignatova and colleagues
[17], the tumor cells have a limited repertoire of responses,
limited by their overall driving genetic mutations [65]a n d
altered epigenetic responses. However, within any cluster of
cells (viewed here as a self organizing system), information
ﬂows between cells may be being nurtured by only a few
glioma stem cells within their tumor-mesenchymal niche. In
thissystem,theorganotypiccellclustersarebeingguidednot
only by their own individually altered response repertoire to
biological eﬀectors (stimuli) but also by inanimate microen-
vironmental conditions (cues) such as access to nutrition,
barriers to spread, and space to proliferate. The information
supplied by the cues is subtle and can be overlooked making
certain emergent properties appear to arise from mysterious
origins [66]. Thus the cytotypic maps drawn by Burger and
Kleihues [2] in which there is marked cytologic heterogene-
ity within the tumor, but relatively monotonous cellular
proﬁles regionally, seem accessible via an understanding of
microregional adaptation to both stimuli and cues. Here,
we see necrosis as a reﬂection of failed adaptation and
angiogenesisandmigrationasviableones,albeitinalimited,
host destructive sense. Although Darwinism may appear as
the correct model, malignant progression and concomitant
increased growth rates are only short-term positives as
cells adapt to their micro-environments. Darwinism, strictly
applied, is based on many generations of the host-agent
interaction and is not the proper model.
In 2000, Hanahan and Weinberg [67] proposed six key
requisites of a malignant cell: “self-suﬃciency in growth
signals, insensitivity to growth-inhibitory signals, evasion
of programmed cell death, limitless replicative potential,
sustained angiogenesis, and tissue invasion and metastasis.”
The tumor stem cell concept addresses the majority of these
requisites in surprisingly, but biologically economical, ways.
They also hypothesized, with little more than histologic
evidence to guide them, that “apparently normal bystanders
such as ﬁbroblasts and endothelial cells must play key
roles in driving tumor cell proliferation.” Again, the tumor
stem cell concept has directly revealed mechanisms whereby
these observations are supported. The ﬁndings noted above
related to glioma stem cells active in their niche provide a
conceptual lens through which these cell to cell and cell to
stroma information signals come into focus. There are many
implications for present and future research.
Many recent experiments have strived to correlate
cytologic structure and expression phenotypes with6 Journal of Oncology
biological function. However, the histologic studies have
been done on formalin-ﬁxed, paraﬃne m b e d d e dt i s s u e s
taken from regions, by deﬁnition, microscopically removed
from the frozen section blocks from which the DNA and
RNA were extracted. The data derived from glioma stem
cell studies indicate that regional expression will be variable
and dependent upon the micro-environment. Grinding
up tissue from which to extract DNA and RNA will only
provide an average answer related to the size of the tissue
studiedbutwillserveasastarting point. Asdataarecollected
from tumors relatively homogeneous with one histologic
type, hypotheses can be generated to be answered by more
precise methods. To address such concerns new techniques
in microdissection, cell culture, and microenvironmental
manipulation in xenografts will have to be developed in
order to better understand the rich, organic interactions
among glioma stem cells and their cellular and mesenchymal
constituents.
To neuropathologists, glioblastoma has long been a
tumor that represented a complex system of migrating pleo-
morphic tumor cells, proliferating blood vessels, inﬁltrating
inﬂammatory cells, and necrosis. Now, the glioma stem
cell concept brings these elements together into a collective
whole interacting with microenvironmental inﬂuences in
complex ways. The new paradigm of glioblastoma biology
will be that genetic changes should be understood in a
three-dimensional framework as they relate not only to
the tumor cells themselves but also to the multicellular
hierarchical unit, not isolated from, but responsive to, its
local milieu. In this way we will come to better appreciate the
impact our therapeutic interventions have on the regional
phenotypic heterogeneity that exists within the tumor and
the intercellular communications directing adaptation and
progression.
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